Wednesday, May 11, 2005
ADP356 is a selective 5HT-2C receptor agonist, which is thought to have effects on food intake. Though it is not supposed to be effective on 5HT-2A or -2B, or on other 5HT receptors, I can't wait for the psychological and physiological side effects to start popping up. If they don't, or at least fail to do so before the drug hits the market, we're all gonna be really sorry we didn't buy Nasdaq: ARNA this morning.
Of course, when said side effects do surface, we'll be really glad to have sold our shares the week before!